argenx SE/$ARGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Ticker
$ARGX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
1,599
ISIN
US04016X1019
Website
argenx SE Metrics
BasicAdvanced
$35B
36.18
$15.94
0.17
-
Price and volume
Market cap
$35B
Beta
0.17
52-week high
$658.93
52-week low
$519.70
Average daily volume
413K
Financial strength
Total debt to equity
0.71
Interest coverage (TTM)
79.79%
Management effectiveness
Valuation
Price to earnings (TTM)
36.18
Price to revenue (TTM)
13.149
Price to book
5.63
Price to tangible book (TTM)
5.82
Growth
Revenue change (TTM)
82.13%
Earnings per share change (TTM)
-382.53%
3-year revenue growth (CAGR)
90.69%
3-year earnings per share growth (CAGR)
11.40%
argenx SE News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of $35B as of June 04, 2025.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 36.18 as of June 04, 2025.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of June 04, 2025.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) has a beta rating of 0.17. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.